Biomarkers in Samples From Young Patients With Neuroblastoma

Children's Oncology Group

Status: Completed

Conditions: Neuroblastoma

Treatments: Genetic: protein expression analysis; Genetic: western blotting; Other: flow cytometry; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01358604

NCI-2011-02855 (Registry Identifier)

COG-ANBL11B2 (Other Identifier)

ANBL11B2 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.

Full description

OBJECTIVES:

Primary

To analyze the expression of ROR1 on the surface of primary neuroblastoma cells. To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.

OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.

Enrollment: 20 patients

Sex: All

Ages: Under 120 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosed with neuroblastoma

  • With or without N-myc amplification

• Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C

• Bone marrow samples from high-risk patients as peripheral blood mononuclear cells (PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow cytometry or slides of bone marrow that can be used for immunohistochemistry

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified